All In Biotech

Drug Trial Radar · NCT06237309

REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of a Single Dose of REGN5381, an NPR1 Monoclonal Antibody Agonist, in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

89

Actual

Start

Apr 11, 2024

Primary completion

Sep 17, 2025

Study completion Dec 29, 2025

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Feb 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should). The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Conditions

  • Heart Failure

Interventions

  • REGN5381Drug

    Single dose intravenous (IV) infusion

  • PlaceboDrug

    Single dose IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Fold Change From Baseline in Circulating N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP)Time frame: Baseline, Day 8

Locations

44 sites in 12 countries. Site status is shown where the registry gives one.

  • Arensia Exploratory Medicine Clinic

    Phoenix, Arizona

  • Harbor UCLA Medical Center

    Torrance, California

  • Flourish Research - Miami (Kendall) (Formerly Clinical Site Partners)

    Miami, Florida

  • Flourish Research - Orlando (Formerly Clinical Site Partners)

    Winter Park, Florida

  • Centre Hospitalier Regional de la Citadelle

    Liège, Belgium

  • Grand Hopital de Charleroi

    Gilly, Hainaut, Belgium

  • Anima Research Center

    Alken, Limburg, Belgium

  • Onze Lieve Vrouw Ziekenhuis Aalst

    Aalst, Oost-Vlaanderen, Belgium

  • UZ Leuven

    Leuven, Vlaams Brabant, Belgium

  • Algemeen Ziekenhuis St Jan Brugge Oostende Av

    Bruges, West Flanders, Belgium

  • Algemeen Ziekenhuis Groeninge

    Kortrijk, West Vlaanderen, Belgium

  • AZ Oostende

    Ostend, West Vlaanderen, Belgium

  • MHAT Haskovo

    Haskovo, Bulgaria

  • University Multiprofile Hospital for Active Treatment Plovdiv

    Plovdiv, Bulgaria

  • Arensia Exploratory Medicine Clinic at MBAL Sveta Sofia

    Sofia, Bulgaria

  • Medicus Services s.r.o.

    Brandýs nad Labem-Stará Boleslav, Czechia

  • Edumed

    Jaroměř, Czechia

  • Fakultni Nemocnice v Motole

    Prague, Central Bohemian, Czechia

  • University Hospital Brno

    Brno, South Moravian, Czechia

  • Arensia Exploratory Medicine at the Research Institute of Clinical Medicine

    Tbilisi, Georgia

  • General University Hospital Attikon

    Chaïdári, Greece

  • Larissa University Hospital

    Larissa, Greece

  • First Cardiology Clinic University of Athens

    Athens, Attica, Greece

  • Athens Naval Hospital

    Athens, Attikh, Greece

  • Pmsi Republican Clinical Hospital Timofei Mosneaga

    Chisinau, Moldova

  • Medical University of Lodz

    Lodz, Poland

  • NZOZ Gemini

    Żychlin, Poland

  • Wojewodzki Szpital Zespolony - Ludwik Rydygier Provincial Hospital

    Torun, Kuyavian-Pomeranian Voivodeship, Poland

  • Clinmedica Research sp zo.o.

    Skierniewice, Łódź Voivodeship, Poland

  • UCK Medical University of Warsaw

    Warsaw, Masovian Voivodeship, Poland

  • Arensia Exploratory Medicine Clinic at Monza Bucharest

    Bucharest, Romania

  • Sc Arensia Exploratory Medicine Srl

    Cluj-Napoca, Romania

  • Worthwhile Clinical Trials

    Benoni, Gauteng, South Africa

  • Into Research

    Groenkloof, Gauteng, South Africa

  • Dr M I Sarvan,R Moodley & partners

    Durban, KwaZulu-Natal, South Africa

  • Kuils River Hospital

    Kuils River, Western Cape, South Africa

  • Korea University Guro Hospital

    Seoul, South Korea

  • Wonju Severance Christian Hospital

    Wŏnju, Gangwon-do, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • Severance Hospital at Yonsei University College of Medicine

    Seoul, Seodaemun-gu, South Korea

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.